TORC vs. KRON, EQ, ALRN, CARM, EGRX, MURA, KZR, MNOV, CKPT, and AEON
Should you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Kronos Bio (KRON), Equillium (EQ), Aileron Therapeutics (ALRN), Carisma Therapeutics (CARM), Eagle Pharmaceuticals (EGRX), Mural Oncology (MURA), Kezar Life Sciences (KZR), MediciNova (MNOV), Checkpoint Therapeutics (CKPT), and AEON Biopharma (AEON). These companies are all part of the "medical" sector.
resTORbio (NASDAQ:TORC) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends.
resTORbio received 123 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 67.14% of users gave resTORbio an outperform vote while only 66.67% of users gave Kronos Bio an outperform vote.
46.2% of resTORbio shares are held by institutional investors. Comparatively, 64.1% of Kronos Bio shares are held by institutional investors. 11.8% of resTORbio shares are held by insiders. Comparatively, 23.4% of Kronos Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Kronos Bio has a consensus target price of $4.13, suggesting a potential upside of 304.41%. Given Kronos Bio's higher possible upside, analysts clearly believe Kronos Bio is more favorable than resTORbio.
resTORbio has a net margin of 0.00% compared to Kronos Bio's net margin of -1,791.87%. Kronos Bio's return on equity of -58.79% beat resTORbio's return on equity.
In the previous week, Kronos Bio had 9 more articles in the media than resTORbio. MarketBeat recorded 9 mentions for Kronos Bio and 0 mentions for resTORbio. resTORbio's average media sentiment score of 0.00 beat Kronos Bio's score of -0.49 indicating that resTORbio is being referred to more favorably in the media.
resTORbio has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500.
resTORbio has higher earnings, but lower revenue than Kronos Bio. resTORbio is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks.
Summary
Kronos Bio beats resTORbio on 10 of the 16 factors compared between the two stocks.
Get resTORbio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
resTORbio Competitors List
Related Companies and Tools
